CRISPR Therapeutics AG — Director's Dealing 2018

May 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-05-14

Reporting Person: Behbahani Ali (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-14	Common Stock	J	199	$0.00	Acquired	199	Direct

Footnotes

F1: NEA Partners 15, L.P. ("NEA Partners 15") made a pro rata distribution for no consideration of an aggregate of 20,879 shares of Common Stock of the Issuer to its limited partners on May 14, 2018. The Reporting Person received 199 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on May 14, 2018.